Souvenaid Strawberry Nutritional Drink (4 x 125ml )

Nutrition Facts - Souvenaid Strawberry

Souvenaid is a milk-based, ready-to-drink oral nutritional supplement containing a patented combination of nutrients (Fortasym Connect®) specifically designed for the dietary management of early Alzheimer's disease. The formula provides essential omega-3 and omega-6 fatty acids, choline, uridine, B vitamins, and other micronutrients to support cognitive function.

Macronutrients

Vitamins

Ingredients

Souvenaid is a milk-based ready-to-drink formula with a patented combination of nutrients designed for early Alzheimer's disease management.

Water, Maltodextrin, Sugar, Fish Oil, Cow's Milk Proteins, Flavouring, Uridine 5'-Monophosphate Disodium Salt, Thickeners (Microcrystalline Cellulose and Sodium Carboxymethylcellulose), Choline Chloride, Calcium Citrate, Soy Lecithin, Acidity Regulator (Citric Acid), Sodium L-Ascorbate, Potassium Citrate, DL-α Tocopheryl Acetate, Magnesium Hydroxide, Sodium Citrate, Potassium Iodide, Ferrous Lactate, Zinc Sulphate, Pyridoxine Hydrochloride, Copper Gluconate, Nicotinamide, Manganese Sulphate, Calcium D-Pantothenate, Pteroymonoglutamic Acid, Thiamin Hydrochloride, Retinyl Acetate, Riboflavin, Sodium Selenite, Chromium Chloride, Sodium Molybdate, Potassium Iodide, Phytomenadione, D-Biotin, Cyanocobalamin, Cholecalciferol

Allergy Advice

For allergens, see ingredients in bold. Contains: Milk, Fish, Soy

Important Notice

Suitable For:

• Early Alzheimer's disease
• Mild cognitive impairment
• Cognitive decline support
• Disease-related malnutrition in neurological conditions

Contra-Indications

Not suitable for patients with galactosaemia.

Precautions

Suitability

Halal and Kosher

Preparation and Directions for Usage

Souvenaid is a ready-to-drink formula that requires no preparation. Simply shake well before opening and consume as directed by your healthcare professional.

Preparation Instructions

1. Shake the bottle well before opening.
2. Open the bottle and consume the entire contents.
3. Serve chilled for best taste.
4. Can be consumed as a beverage or used in cooking.
5. Once opened, consume immediately or refrigerate and use within 24 hours.

Dosage Information

The recommended dosage is 1 bottle (125ml) per day as a supplement to normal diet. Consume at any time during the day. Best served chilled.

Storage & Shelf Life

Storage: Store in a dry, cool place (5-25°C). Once opened, close the bottle and store in a refrigerator. Discard unused contents after 24 hours.

Shelf Life: 12 months unopened. Best before date: see bottom of bottle.

Product Information

Format: Ready-to-Drink Beverage | Pack Size: 125ml Bottle | Flavour: Strawberry | Dosage: 1 bottle per day

Manufacturer Information

Nutricia Ltd. Pack Size: 125ml Bottle | Format: Ready-to-Drink Beverage | Medical Use: Early Alzheimer's Disease Management

Medical Supervision

This product must be used under medical supervision. Not intended as sole source of nutrition. Use only as a supplement to normal diet. Suitable for adults only (18+ years).

Special Considerations

Fortasym Connect® Patented Formula: Souvenaid contains a unique combination of nutrients specifically designed to support cognitive function in early Alzheimer's disease. The formula includes high levels of DHA and EPA (omega-3 fatty acids), along with choline, uridine, and other essential micronutrients.

Ready-to-Drink Convenience: Unlike powdered formulas, Souvenaid requires no preparation, making it convenient for patients and caregivers. The individual 125ml bottles provide precise dosing and easy portability.

Flavour Variety: Available in multiple flavours (Strawberry and Vanilla) to improve palatability and encourage compliance with dietary management.

ACBS Approved: Souvenaid is approved by the Advisory Committee on Borderline Substances (ACBS) and is prescribable on form FP10 (GP10 in Scotland) for the dietary management of early Alzheimer's disease.

Clinical Evidence: Souvenaid with Fortasym Connect® has been clinically studied for its role in supporting cognitive function in patients with early Alzheimer's disease and mild cognitive impairment.